Tag Archives: Seegene

July 2022—Seegene has developed a PCR test to detect monkeypox virus. The Novaplex MPXV assay, for research use only, was developed using the company’s AI-based automated test development system and can identify positive cases of the monkeypox virus in 90 minutes.

June 2022—Seegene announced that its Allplex RV Master Assay has achieved CE-IVD marking and received approval from Australia’s Therapeutic Goods Administration.

Dec. 13, 2021—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only.

Sept. 29, 2021—Seegene unveiled its first fully automated PCR testing system, Starlet-AIOS, at the 2021 AACC annual meeting, Sept. 26–30, in Atlanta.

May 2021—Seegene announced it has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the FDA for emergency use authorization.

March 2021—Seegene announced it has developed the first COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.

March 2, 2021—Seegene announced it has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the FDA for emergency use authorization.

Feb. 9, 2021–Seegene announced it has developed the first COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.

October 2017—Seegene presented its Seegene Random Access System at the 69th AACC Annual Clinical Lab Expo in San Diego. The system provides order to report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.

November 2015—Agena Bioscience introduced the Chip prep moduleto automate sample handling after polymerase chain reaction for the MassArray 96-well System. This enables laboratories to operate the MassArray System largely unattended for high-throughput, multiplex genetic analysis.

Qiagen announced a collaboration with Seegene in which Seegene will develop a menu of multiplex assay panels for Qiagen’s modular QIAsymphony RGQ MDx automation platform.

July 2015—Seegene announced that its Allplex Gastrointestinal Full Panel Assay has received the CE-IVD mark, enabling marketing in Europe and certain other countries.

May 2015—Seegene announced that the Food and Drug Administration has granted 510(k) market clearance for its TOCE-based herpes simplex virus types 1 and 2 assay. This is the first product Seegene has taken through the FDA, and it opens the way for the company’s other planned FDA submissions of multiplex real-time PCR reagents.

May 2015—Seegene announced that Health Canada has approved its six-target Allplex Respiratory Panel 5 assay, which identifies influenza virus A and B, RSV A and B, and influenza A virus subtypes H1 and H3.

February 2014—Beckman Coulter Diagnostics and Seegene announced a molecular diagnostic assay supply agreement. Under the agreement, Seegene will begin manufacturing reagents designed exclusively for Beckman Coulter’s Veris MDx System, a sample-to-answer molecular diagnostics instrument.

January 2015—Seegene is introducing the first three comprehensive Allplex assays using its next-generation qPCR technology, called MuDT. The assay launch menu includes a 26-target Respiratory Full Panel, a 26-target Gastrointestinal Infection Full Panel, and a 27-target Sexually Transmitted Infection Full Panel.

Seegene has launched its multiple mutation detection technology to accelerate the development of companion diagnostic tests. The technology transforms conventional real-time instruments into powerful systems to simultaneously detect multiple mutation targets in a single channel. Seegene has extended the capabilities of its real-time PCR technology to simultaneously detect more than 20 different mutations, including insertions, deletions, and point mutations, in ...

Seegene announced that BioMérieux has licensed the company’s DPO and TOCE technologies for the development of multiplexed tests for food safety.

Seegene has entered into a collaborative agreement with Eidia, the in vitro diagnostics subsidiary arm of Eisai Co., headquartered in Japan. Through this agreement, Eidia gains access to Seegene’s portfolio of Toce technology-based multiplex molecular diagnostic tests for the Japanese diagnostic test market.

Seegene’s novel real-time array technology is designed to accelerate the development of point-of-care testing by eliminating steps that normally follow PCR amplification, and that are required for conventional arrays. The new technology unifies all the steps into one. There is no size limitation for the PCR amplicon, and the array technology requires no asymmetric PCR, denaturation of the PCR amplicon, target specific primer extension, signal amplification, or washing step.